Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by MirrorWorldManon Sep 26, 2018 1:54pm
106 Views
Post# 28694667

RE:Un-named center and dermatologist?

RE:Un-named center and dermatologist?I doubt it’s a company at all. Sounds like a single derm in a clinic setting. Dermatologists are all about making money and are among the busiest and most efficiently of any specialty. I have heard them talk. They are not cheap and somebody has to pay them trial honorariums for staff and doctor paperwork and time. If the data is to be published then add a significant amount of time and money. Let’s hope it does not get published, as nobody will see the data for a while. My guess is that the quick October turnaround and no announcement  suggests that the data will remain internal proprietary. For use with negotiations. So much for the cheap low risk model of letting the partner do all the work and SBM reaps the benefits. Doesn’t quite work like that does it Howie?
Bullboard Posts